All In Biotech

Drug Trial Radar · NCT06366698

Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

Early Intravenous Versus Oral Iron for Ferritin-Defined Iron Deficiency in Pregnancy: A Prospective Comparative Study

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

518

Actual

Start

Nov 21, 2023

Primary completion

Sep 12, 2025

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Arrowhead Regional Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to assess whether administering intravenous iron early in pregnancy, compared to standard oral iron treatment, can enhance hemoglobin levels before delivery and reduce the need for blood transfusions in patients with iron deficiency anemia. Patients diagnosed with iron deficiency anemia were randomly assigned to receive either oral or intravenous iron. Before treatment initiation, patients completed a symptom questionnaire baseline hemoglobin, and ferritin levels were measured. Follow-up visits occurred four weeks later and at 24 to 28 weeks gestation, involving reassessment of symptoms, laboratory testing, and monitoring of treatment adherence. Final hemoglobin levels were determined before delivery, and data on the need for blood transfusion at delivery were recorded.

Conditions

  • Iron Deficiency Anemia of Pregnancy

Interventions

  • Venofer 200 MG Per 10 ML InjectionDrug

    200 mg IV every 2 days until the targeted dose

  • Ferrous sulfateDrug

    Take 1 tablet every other day with lemon/orange juice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemoglobin differenceTime frame: Hemoglobin level obtained prior to treatment and then 4 weeks later
  2. Ferritin differenceTime frame: Ferritin level obtained prior to treatment and then 4 weeks later

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Arrowhead Regional Medical Center

    Colton, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.